Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2013-04-23 | Ms. Sharp is Chief Financial Officer and Senior Vice President, Finance of Ultragenyx Pharmaceutical. Ms. Sharp served as Vice President and Chief Financial Officer of Agenus from 2006 to 2012, and was most recently appointed a member of the Board effective May 11, 2012. She joined Agenus in 2003 and held increasing roles of responsibility spanning strategic planning, corporate development, investor relations, corporate finance and business development activities. Prior to Agenus, Ms. Sharp held similar roles at Elan Pharmaceuticals from 1998 to 2003, including serving as chief of staff to the Chairman of the Board of Directors during that companys restructuring. With 16 years of industry experience, Ms. Sharp has spearheaded numerous financing and business development transactions that have been critical to the success of Agenus and Elan. Prior to Elan, Ms. Sharp was a management consultant at McKinsey & Company as well as an investment banker at Goldman Sachs, specializing in pharmaceuticals and medical devices. Ms. Sharp holds both a bachelors degree and a masters degree in business administration from Harvard University. |
| 2014-03-10 | Ms. Sharp holds both a bachelor’s degree and a master’s degree in business administration from Harvard University. |
| 2015-04-30 | Ms. Sharp holds both a bachelor’s degree and a master’s degree in business administration from Harvard University. |
| 2016-04-28 | Ms. Sharp is Chief Financial Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc. and a member of the Board of the TB Alliance. Ms. Sharp served as Chief Financial Officer of Agenus from 2006 to May 2012, and was appointed a member of the Board in May 2012. She joined Agenus in 2003 and held increasing roles of responsibility spanning strategic planning, corporate development, investor relations, corporate finance and business development activities. Prior to Agenus, Ms. Sharp held similar roles at Elan Pharmaceuticals from 1998 to 2003, including serving as chief of staff to the Chairman of the Board of Directors during that companys restructuring. Prior to Elan, Ms. Sharp was a management consultant at McKinsey & Company as well as an investment banker at Goldman Sachs, specializing in pharmaceuticals and medical devices. Ms. Sharp holds both a bachelors degree and a masters degree in business administration from Harvard University. |
| 2017-05-08 | Ms. Sharp holds both a bachelors degree and a masters degree in business administration from Harvard University. |
| Filing Date | Source Excerpt |
|---|---|
| 2020-04-09 | Shalini Sharp has served on the Board of Directors since February 2020. Ms. Sharp is the Chief Financial Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, holding the position of Chief Financial Officer since May 2012 and the position of Executive Vice President since January 2016. ... The Board of Directors has also determined that Ms. Sharp is an “audit committee financial expert” within the meaning of item 407(d)(5) of SEC Regulation S-K. |
| 2021-04-09 | Shalini Sharp has served on the Board of Directors since February 2020. The members of the Audit Committee for 2020 were Richard F. Pops, Shalini Sharp and Stephen A. Sherwin, M.D. The Companys Compensation Committee consists of directors George J. Morrow, Richard F. Pops and Shalini Sharp. For 2020, directors who are not employees of the Company earned a $55,000 annual cash retainer. Each other director who was a member of the Audit Committee earned an additional annual cash retainer of $12,000, and each other director who was a member of the Compensation Committee earned an additional annual cash retainer of $12,000. Additionally, for 2020, each non-employee director received a grant of a nonstatutory stock option to purchase 6,018 shares of the Companys common stock, representing an approximate value of $400,000 on the date of the 2020 Annual Meeting of Stockholders. Upon her appointment to the board in February 2020, Shalini Sharp received a grant of a nonstatutory stock option to purchase 15,000 shares of the Companys common stock. The following table sets forth the compensation earned for the fiscal year ended December 31, 2020 by the directors of the Company named below: Shalini Sharp Fees Earned or Paid in Cash $45,569 Option Awards $822,459 Total $868,027. |
| 2022-04-07 | Shalini Sharp has served on the Board of Directors since February 2020. ... The members of the Audit Committee for 2021 were Richard F. Pops, Shalini Sharp, and Stephen A. Sherwin, M.D., with Ms. Sharp serving as the Audit Committee Chair. The Company’s Compensation Committee consists of directors George J. Morrow, Richard F. Pops, and Shalini Sharp, with Mr. Pops serving as the Compensation Committee Chair. ... The following table sets forth the compensation earned for the fiscal year ended December 31, 2021 by the directors of the Company named below: Shalini Sharp $88,464 fees earned in cash and $400,003 option awards totaling $488,467. |
| 2023-04-05 | Shalini Sharp has served on the Board of Directors since February 2020. She also serves on the Board of Directors of Mirati Therapeutics, Sutro Biopharma and Organon & Co. Previously, Ms. Sharp served on the Board of Directors of precision Biosciences, TB Alliance, Array Biopharma, prior to its acquisition by Pfizer, as well as on the Board of Directors of Panacea Acquisition Corp., prior to its merger with Nuvation Bio. Ms. Sharp has held the positions of Chief Financial Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases, and Chief Financial Officer at Agenus Inc., a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer. She served on the Board of Directors of Agenus for several years after her departure. Ms. Sharp previously served in strategic planning and as chief of staff to the Chairman of the Board of Directors at Elan Pharmaceuticals during the company’s restructuring. Ms. Sharp has also served as a management consultant at McKinsey & Company and an investment banker at Goldman Sachs, specializing in healthcare at both companies. She holds a B.A., magna cum laude, and an M.B.A. from Harvard University. The Company’s Audit Committee for 2022 were Richard F. Pops, Shalini Sharp, and Stephen A. Sherwin, M.D., with Ms. Sharp serving as the Audit Committee Chair. |
| 2024-04-10 | Shalini Sharp has served on the Board of Directors since February 2020. ... Ms. Sharp has held the positions of Chief Financial Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases, and Chief Financial Officer at Agenus Inc., a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer. ... The Company’s Audit Committee is comprised entirely of directors who meet the independence requirements set forth in Nasdaq Stock Market Rule 5605(c)(2)(A). ... The members of the Audit Committee for 2023 were Richard F. Pops, Shalini Sharp, and Stephen A. Sherwin, M.D., with Ms. Sharp serving as the Audit Committee Chair. ... The Company’s Compensation Committee consists of directors George J. Morrow, Richard F. Pops, and Shalini Sharp, with Mr. Pops serving as the Compensation Committee Chair. ... For fiscal 2023, directors who are not employees of the Company earned a $60,000 annual cash retainer. ... For fiscal 2023, on the date of the 2023 Annual Meeting of Stockholders, each continuing non-employee director received an annual equity award with an approximate grant date value of $400,000. ... The following table sets forth the compensation earned for the fiscal year ended December 31, 2023 by the directors of the Company named below: ... Shalini Sharp $97,000 cash fees, $200,043 option awards, $200,067 stock awards, total $497,110. |
Data sourced from SEC filings. Last updated: 2026-02-03